India's big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official. The lengthy timeline is a concern not only in India but around the world, as India's pharmaceutical firms supply a third of the drugs sold in the United States and a large percentage in other countries. US and European Union regulators have called on India's $16 billion pharmaceutical industry to step up their efforts if it wants to continue to dominate the generic ...
Drugmakers need time to meet global standards: Indian Pharma Association
India's firms supply a third of the drugs sold in the US and a large percentage in other countries